The Patent Finder
US

Composition and Dosage Form Comprising a Particle Formulation and Suspending Vehicle

US 7,964,183 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Nov 15, 2024 · High confidence

Filed Dec 29, 2009 as application 12/655,397 · Granted Jun 21, 2011
Base term, 20 years from filing
Today
20 years from filing
Term ended Nov 15, 2024
2004 2026
Clock starts
Nov 15, 2004
Term ended
Nov 15, 2024
Granted
Jun 21, 2011
base term after the term ends fee events Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,731,947, to Nov 15, 2024. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Nov 15, 2004, when application 10/988,716, the earliest non-provisional in its chain, was filed (this one was filed Dec 29, 2009)Nov 15, 2024High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,731,947)resolves to Nov 15, 2024, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderNov 15, 2024High confidence

This family

Application 10/742,730Abandoned
not computed
not computed
US 7,731,947In force
May 2028
May 2028
Application PCT/US2004/038409PCT application
no patent term
no patent term
Application 12/315,194Abandoned
not computed
not computed
US 7,964,183this patent
Nov 2024
Nov 2024
US 8,257,691Term ended
Nov 2024
Nov 2024
US 8,398,967Term ended
May 2024
May 2024
US 9,724,293Lapsed on the fee record
Aug 2021
Aug 2021
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Sep 8, 2010
Reel 24953, frame 525
Intarcia Therapeutics, Inc.Oxford Finance Corporation; Silicon Valley BankSecurity Agreement
Sep 8, 2010
reel/frame not recorded
Intarcia Therapeutics, Inc.Oxford Finance CorporationSecurity Agreement
Sep 8, 2010
reel/frame not recorded
Intarcia Therapeutics, Inc.Silicon Valley BankSecurity Agreement
Sep 23, 2011
Reel 26962, frame 62
Oxford Finance Corporation; Silicon Valley BankIntarcia Therapeutics, Inc.Release of Security Interest
Nov 14, 2012
Reel 29299, frame 678
Intarcia Therapeutics, Inc.U.S. Bank National Association, as Collateral AgentSecurity Agreement
Mar 23, 2015
Reel 35233, frame 470
Alza CorporationIntarcia Therapeutics Inc.Assignment of Assignor's Interest
Mar 23, 2015
Reel 35233, frame 597
Eliaz, Rom Ezer; Zhang, Yuanpeng; Rohloff, Catherine Manya; Weeks, Eric William; Junnarkar, GunjanAlza CorporationAssignment of Assignor's Interest
Oct 23, 2015
Reel 36942, frame 544
U.S. Bank National Association, as Collateral AgentIntarcia Therapeutics, Inc.Release of Security Interest
Oct 9, 2019
Reel 50673, frame 20
Intarcia Therapeutics, Inc.; Intarcia Ireland LimitedMidcap Financial Trust, As AgentSecurity Interest
Oct 23, 2019
Reel 50801, frame 267
Intarcia Therapeutics, Inc.Baupost Private Investments Bviv-3, L.L.C., as Collateral AgentSecurity Interest
Jan 29, 2020
Reel 51739, frame 453
Baupost Private Investments Bviv-3, L.L.C. as Collateral AgentIntarcia Therapeutics, Inc.Release of Security Interest
Apr 17, 2020
Reel 52433, frame 1
Midcap Financial Trust, As AgentIntarcia Therapeutics, Inc.; Intarcia Ireland LimitedRelease of Security Interest
Apr 17, 2020
reel/frame not recorded
Midcap Financial Trust, As AgentIntarcia Therapeutics, Inc.Release of Security Interest
Apr 17, 2020
reel/frame not recorded
Midcap Financial Trust, As AgentIntarcia Ireland LimitedRelease of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited